Skip to content
lifestyle.briefmobile.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Polaryx Therapeutics, Inc.
Polaryx Therapeutics Announces Closing of $10 Million Private Placement Equity Financing to Support Launch of SOTERIA Phase 2 Basket Trial
May 28, 2026
Polaryx Therapeutics Receives GHP Magazine’s Healthcare & Pharmaceuticals Awards
May 21, 2026
Polaryx Therapeutics to Participate in National Tay-Sachs & Allied Diseases Association Annual Family Conference
May 8, 2026
Polaryx Therapeutics Receives U.S. FDA Fast Track Designations for All Four Indications to be Evaluated in the SOTERIA Basket Trial
May 8, 2026
Polaryx Therapeutics Recognized with Pinnacle Award for Excellence in Pediatric Care
May 7, 2026
Polaryx Therapeutics To Participate In The 25th Annual Needham Virtual Healthcare Conference
May 5, 2026
Polaryx Therapeutics Receives FDA Fast Track Designation for PLX‑200 for Late‑Infantile Neuronal Ceroid Lipofuscinosis (CLN2 Disease)
May 3, 2026
Polaryx Therapeutics Deepens Engagement with the Krabbe Disease Community Through Scientific and Patient Advocacy Events
May 2, 2026
Polaryx Therapeutics Marks Rare Disease Day, Reaffirming Commitment to Patients with Rare Pediatric Lysosomal Storage Disorders
April 30, 2026
Polaryx Therapeutics Selects Contract Research Organization for SOTERIA Phase 2 Basket Trial
April 28, 2026
1
2
Next Page
→